{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T22:47:14Z","timestamp":1787784434382,"version":"build-2784847793"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472711, U21A20382 to W.X. and 82472789 to Z.Y.Z"],"award-info":[{"award-number":["82472711, U21A20382 to W.X. and 82472789 to Z.Y.Z"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472711, U21A20382 to W.X. and 82472789 to Z.Y.Z"],"award-info":[{"award-number":["82472711, U21A20382 to W.X. and 82472789 to Z.Y.Z"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70725-4","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:34:42Z","timestamp":1774632882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High-risk EBV promotes immune evasion in nasopharyngeal carcinoma by upregulating HLA-DP via the encoded BALF2-HR variant"],"prefix":"10.1038","volume":"17","author":[{"given":"Yi","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijia","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinglang","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongke","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-3613","authenticated-orcid":false,"given":"Zhaojian","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2641-5434","authenticated-orcid":false,"given":"Bo","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2007-9898","authenticated-orcid":false,"given":"Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-2050","authenticated-orcid":false,"given":"Can","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0648-0565","authenticated-orcid":false,"given":"Zhaoyang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6116-7985","authenticated-orcid":false,"given":"Junshang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1635-8173","authenticated-orcid":false,"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"70725_CR1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt\u2019s Lymphoma. Lancet 1, 702\u2013703 (1964).","journal-title":"Lancet"},{"key":"70725_CR2","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein-barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"70725_CR3","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1182\/bloodadvances.2023011506","volume":"8","author":"MC Siciliano","year":"2024","unstructured":"Siciliano, M. C. et al. Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior. Blood Adv. 8, 4330\u20134343 (2024).","journal-title":"Blood Adv."},{"key":"70725_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C L\u00f3pez","year":"2022","unstructured":"L\u00f3pez, C. et al. Burkitt lymphoma. Nat. Rev. Dis. Prim. 8, 78 (2022).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"70725_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse, E. et al. How we treat NK\/T-cell lymphomas. J. Hematol. Oncol. 15, 74 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"70725_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"70725_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cac2.12218","volume":"41","author":"LL Tang","year":"2021","unstructured":"Tang, L. L. et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun. 41, 1195\u20131227 (2021).","journal-title":"Cancer Commun."},{"key":"70725_CR8","doi-asserted-by":"publisher","first-page":"100474","DOI":"10.1016\/j.xgen.2023.100474","volume":"4","author":"M Xu","year":"2024","unstructured":"Xu, M. et al. Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: Assessment of interaction and mediation. Cell Genom. 4, 100474 (2024).","journal-title":"Cell Genom."},{"key":"70725_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","volume":"32","author":"P Bossi","year":"2021","unstructured":"Bossi, P. et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann. Oncol. 32, 452\u2013465 (2021).","journal-title":"Ann. Oncol."},{"key":"70725_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124\u20131135 (2019).","journal-title":"N. Engl. J. Med."},{"key":"70725_CR11","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet 51, 1131\u20131136 (2019).","journal-title":"Nat. Genet"},{"key":"70725_CR12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood.V87.4.1579.bloodjournal8741579","volume":"87","author":"V Schuster","year":"1996","unstructured":"Schuster, V. et al. Common Epstein-Barr virus (EBV) type-1 variant strains in both malignant and benign EBV-associated disorders. Blood 87, 1579\u20131585 (1996).","journal-title":"Blood"},{"key":"70725_CR13","doi-asserted-by":"crossref","unstructured":"Tu, C. et al. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens. J. Virol. 91, e00301\u201317 (2017).","DOI":"10.1128\/JVI.00301-17"},{"key":"70725_CR14","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1093\/carcin\/bgy108","volume":"39","author":"C Tu","year":"2018","unstructured":"Tu, C. et al. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. Carcinogenesis 39, 1517\u20131528 (2018).","journal-title":"Carcinogenesis"},{"key":"70725_CR15","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1084\/jem.185.9.1605","volume":"185","author":"NM Steven","year":"1997","unstructured":"Steven, N. M. et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J. Exp. Med. 185, 1605\u20131617 (1997).","journal-title":"J. Exp. Med."},{"key":"70725_CR16","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1128\/JVI.02175-10","volume":"85","author":"AJ Rennekamp","year":"2011","unstructured":"Rennekamp, A. J. & Lieberman, P. M. Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J. Virol. 85, 2837\u20132850 (2011).","journal-title":"J. Virol."},{"key":"70725_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04369-22","volume":"11","author":"TY Chao","year":"2023","unstructured":"Chao, T. Y. et al. Subcellular distribution of BALF2 and the role of rab1 in the formation of Epstein-Barr virus cytoplasmic assembly compartment and virion release. Microbiol. Spectr. 11, e0436922 (2023).","journal-title":"Microbiol. Spectr."},{"key":"70725_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annonc.2022.11.011","volume":"34","author":"P Bossi","year":"2023","unstructured":"Bossi, P. et al. ESMO-EURACAN Clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann. Oncol. 34, 247\u2013250 (2023).","journal-title":"Ann. Oncol."},{"key":"70725_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","volume":"34","author":"ATC Chan","year":"2023","unstructured":"Chan, A. T. C. et al. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann. Oncol. 34, 251\u2013261 (2023).","journal-title":"Ann. Oncol."},{"key":"70725_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41422-020-00402-8","volume":"30","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res. 30, 950\u2013965 (2020).","journal-title":"Cell Res."},{"key":"70725_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/346470a0","volume":"346","author":"SJ Lu","year":"1990","unstructured":"Lu, S. J. et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346, 470\u2013471 (1990).","journal-title":"Nature"},{"key":"70725_CR22","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/ng.601","volume":"42","author":"JX Bei","year":"2010","unstructured":"Bei, J. X. et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat. Genet. 42, 599\u2013603 (2010).","journal-title":"Nat. Genet."},{"key":"70725_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41375-018-0324-5","volume":"33","author":"RJ Peng","year":"2019","unstructured":"Peng, R. J. et al. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma. Leukemia 33, 1451\u20131462 (2019).","journal-title":"Leukemia"},{"key":"70725_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04112-8","volume":"21","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. Comprehensive single-cell transcriptomic and proteomic analysis reveals NK cell exhaustion and unique tumor cell evolutionary trajectory in non-keratinizing nasopharyngeal carcinoma. J. Transl. Med. 21, 278 (2023).","journal-title":"J. Transl. Med."},{"key":"70725_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/labinvest.2015.69","volume":"95","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. Epstein-Barr virus BZLF1 protein impairs accumulation of host DNA damage proteins at damage sites in response to DNA damage. Lab Invest. 95, 937\u2013950 (2015).","journal-title":"Lab Invest."},{"key":"70725_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-083122-040929","volume":"42","author":"Z Steier","year":"2024","unstructured":"Steier, Z. et al. The CD4 Versus CD8 T Cell Fate Decision: A Multiomics-Informed Perspective. Annu. Rev. Immunol. 42, 235\u2013258 (2024).","journal-title":"Annu. Rev. Immunol."},{"key":"70725_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"70725_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.cell.2018.08.048","volume":"175","author":"R Marty Pyke","year":"2018","unstructured":"Marty Pyke, R. et al. Evolutionary pressure against MHC class II binding cancer mutations. Cell 175, 416\u2013428 (2018).","journal-title":"Cell"},{"key":"70725_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1146\/annurev-immunol-041015-055420","volume":"34","author":"ER Unanue","year":"2016","unstructured":"Unanue, E. R., Turk, V. & Neefjes, J. Variations in MHC class II antigen processing and presentation in health and Disease. Annu. Rev. Immunol. 34, 265\u2013297 (2016).","journal-title":"Annu. Rev. Immunol."},{"key":"70725_CR30","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi, T. et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity 55, 912\u2013924.e8 (2022).","journal-title":"Immunity"},{"key":"70725_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s42255-020-00280-9","volume":"2","author":"F Franco","year":"2020","unstructured":"Franco, F. et al. Metabolic and epigenetic regulation of T-cell exhaustion. Nat. Metab. 2, 1001\u20131012 (2020).","journal-title":"Nat. Metab."},{"key":"70725_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41590-022-01224-z","volume":"23","author":"JA Belk","year":"2022","unstructured":"Belk, J. A., Daniel, B. & Satpathy, A. T. Epigenetic regulation of T cell exhaustion. Nat. Immunol. 23, 848\u2013860 (2022).","journal-title":"Nat. Immunol."},{"key":"70725_CR33","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ng.3576","volume":"48","author":"F Zhou","year":"2016","unstructured":"Zhou, F. et al. Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease. Nat. Genet. 48, 740\u2013746 (2016).","journal-title":"Nat. Genet."},{"key":"70725_CR34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.cell.2025.02.014","volume":"188","author":"Y Jiang","year":"2025","unstructured":"Jiang, Y. et al. Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell 188, 2354\u20132371 (2025).","journal-title":"Cell"},{"key":"70725_CR35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","volume":"23","author":"C Guy","year":"2022","unstructured":"Guy, C. et al. LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation. Nat. Immunol. 23, 757\u2013767 (2022).","journal-title":"Nat. Immunol."},{"key":"70725_CR36","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1016\/j.cell.2025.06.004","volume":"188","author":"J Du","year":"2025","unstructured":"Du, J. et al. Proximity between LAG-3 and the T cell receptor guides suppression of T cell activation and autoimmunity. Cell 188, 4025\u20134042 (2025).","journal-title":"Cell"},{"key":"70725_CR37","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews, L. P. et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-\u03b3-dependent anti-tumor immunity. Cell 187, 4355\u20134372 (2024).","journal-title":"Cell"},{"key":"70725_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41392-023-01381-z","volume":"8","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. AlphaFold2 and its applications in the fields of biology and medicine. Signal Transduct. Target Ther. 8, 115 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"70725_CR39","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2174\/156802608786786624","volume":"8","author":"S Vilar","year":"2008","unstructured":"Vilar, S., Cozza, G. & Moro, S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr. Top. Med Chem. 8, 1555\u20131572 (2008).","journal-title":"Curr. Top. Med Chem."},{"key":"70725_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2018.12.001","volume":"176","author":"C Brownlee","year":"2019","unstructured":"Brownlee, C. & Heald, R. Importin \u03b1 partitioning to the plasma membrane regulates intracellular scaling. Cell 176, 805\u2013815 (2019).","journal-title":"Cell"},{"key":"70725_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-023-00849-x","volume":"23","author":"WC Chou","year":"2023","unstructured":"Chou, W. C. et al. The NLR gene family: from discovery to present day. Nat. Rev. Immunol. 23, 635\u2013654 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"70725_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28479-2","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1. Nat. Commun. 13, 866 (2022).","journal-title":"Nat. Commun."},{"key":"70725_CR43","doi-asserted-by":"publisher","first-page":"e1012263","DOI":"10.1371\/journal.ppat.1012263","volume":"20","author":"KW Wong","year":"2024","unstructured":"Wong, K. W. et al. Meta-analysis of Epstein-Barr virus genomes in Southern Chinese identifies genetic variants and high risk viral lineage associated with nasopharyngeal carcinoma. PLoS Pathog. 20, e1012263 (2024).","journal-title":"PLoS Pathog."},{"key":"70725_CR44","doi-asserted-by":"publisher","first-page":"106941","DOI":"10.1016\/j.oraloncology.2024.106941","volume":"157","author":"CY Lim","year":"2024","unstructured":"Lim, C. Y. et al. Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression. Oral. Oncol. 157, 106941 (2024).","journal-title":"Oral. Oncol."},{"key":"70725_CR45","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/cas.15381","volume":"113","author":"S Kondo","year":"2022","unstructured":"Kondo, S. et al. EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region. Cancer Sci. 113, 2446\u20132456 (2022).","journal-title":"Cancer Sci."},{"key":"70725_CR46","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1182\/blood.V89.5.1665","volume":"89","author":"NS Prang","year":"1997","unstructured":"Prang, N. S. et al. Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state. Blood 89, 1665\u20131677 (1997).","journal-title":"Blood"},{"key":"70725_CR47","doi-asserted-by":"publisher","first-page":"21557","DOI":"10.1074\/jbc.M109.015685","volume":"284","author":"S Nakayama","year":"2009","unstructured":"Nakayama, S. et al. Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein. J. Biol. Chem. 284, 21557\u201321568 (2009).","journal-title":"J. Biol. Chem."},{"key":"70725_CR48","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.ebiom.2022.104357","volume":"86","author":"L Ka-Yue Chow","year":"2022","unstructured":"Ka-Yue Chow, L. et al. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma. EBioMedicine 86, 104357 (2022).","journal-title":"EBioMedicine"},{"key":"70725_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01625-6","volume":"21","author":"JA Miller","year":"2022","unstructured":"Miller, J. A. et al. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma. Mol. Cancer 21, 154 (2022).","journal-title":"Mol. Cancer"},{"key":"70725_CR50","doi-asserted-by":"crossref","first-page":"581","DOI":"10.5732\/cjc.014.10208","volume":"33","author":"LS Young","year":"2014","unstructured":"Young, L. S. & Dawson, C. W. Epstein-Barr virus and nasopharyngeal carcinoma. Chin. J. Cancer 33, 581\u2013590 (2014).","journal-title":"Chin. J. Cancer"},{"key":"70725_CR51","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-20-4321","volume":"81","author":"J Ge","year":"2021","unstructured":"Ge, J. et al. Epstein-Barr virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 81, 5074\u20135088 (2021).","journal-title":"Cancer Res."},{"key":"70725_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2023.12.020","volume":"42","author":"XJ Du","year":"2024","unstructured":"Du, X. J. et al. Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell 42, 464\u2013473 (2024).","journal-title":"Cancer Cell"},{"key":"70725_CR53","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","volume":"403","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 403, 2720\u20132731 (2024).","journal-title":"Lancet"},{"key":"70725_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-92","volume":"8","author":"H Liu","year":"2009","unstructured":"Liu, H. et al. LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells. Mol. Cancer 8, 92 (2009).","journal-title":"Mol. Cancer"},{"key":"70725_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41587-019-0289-6","volume":"37","author":"J Racle","year":"2019","unstructured":"Racle, J. et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nat. Biotechnol. 37, 1283\u20131286 (2019).","journal-title":"Nat. Biotechnol."},{"key":"70725_CR56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.immuni.2020.12.005","volume":"54","author":"JG Abelin","year":"2021","unstructured":"Abelin, J. G. et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity 54, 388 (2021).","journal-title":"Immunity"},{"key":"70725_CR57","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/s41590-019-0448-4","volume":"20","author":"A Niehrs","year":"2019","unstructured":"Niehrs, A. et al. A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. Nat. Immunol. 20, 1129\u20131137 (2019).","journal-title":"Nat. Immunol."},{"key":"70725_CR58","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1500140","volume":"373","author":"EW Petersdorf","year":"2015","unstructured":"Petersdorf, E. W. et al. High HLA-DP expression and graft-versus-host disease. N. Engl. J. Med. 373, 599\u2013609 (2015).","journal-title":"N. Engl. J. Med."},{"key":"70725_CR59","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1182\/blood.2022015860","volume":"139","author":"EW Petersdorf","year":"2022","unstructured":"Petersdorf, E. W. et al. HLA-DQ heterodimers in hematopoietic cell transplantation. Blood 139, 3009\u20133017 (2022).","journal-title":"Blood"},{"key":"70725_CR60","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41591-024-02944-5","volume":"30","author":"AJ Mentzer","year":"2024","unstructured":"Mentzer, A. J. et al. High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response. Nat. Med. 30, 1384\u20131394 (2024).","journal-title":"Nat. Med."},{"key":"70725_CR61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/cmi.2013.52","volume":"11","author":"Z Duan","year":"2014","unstructured":"Duan, Z. et al. Activation of the Ig Ialpha1 promoter by the transcription factor Ets-1 triggers Ig Ialpha1-Calpha1 germline transcription in epithelial cancer cells. Cell Mol. Immunol. 11, 197\u2013205 (2014).","journal-title":"Cell Mol. Immunol."},{"key":"70725_CR62","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","volume":"25","author":"ML Axelrod","year":"2019","unstructured":"Axelrod, M. L. et al. Biological consequences of MHC-II expression by tumor cells in cancer. Clin. Cancer Res. 25, 2392\u20132402 (2019).","journal-title":"Clin. Cancer Res."},{"key":"70725_CR63","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","volume":"41","author":"SL Topalian","year":"2023","unstructured":"Topalian, S. L. et al. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy. Cancer Cell 41, 1551\u20131566 (2023).","journal-title":"Cancer Cell"},{"key":"70725_CR64","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","volume":"187","author":"SF Ngiow","year":"2024","unstructured":"Ngiow, S. F. et al. LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell 187, 4336\u20134354 (2024).","journal-title":"Cell"},{"key":"70725_CR65","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","volume":"24","author":"V Aggarwal","year":"2023","unstructured":"Aggarwal, V., Workman, C. J. & Vignali, D. A. A. LAG-3 as the third checkpoint inhibitor. Nat. Immunol. 24, 1415\u20131422 (2023).","journal-title":"Nat. Immunol."},{"key":"70725_CR66","doi-asserted-by":"publisher","first-page":"957208","DOI":"10.3389\/fonc.2022.957208","volume":"12","author":"O Jimenez","year":"2022","unstructured":"Jimenez, O. et al. PD-1 and LAG-3 expression in EBV-associated pediatric Hodgkin lymphoma has influence on survival. Front. Oncol. 12, 957208 (2022).","journal-title":"Front. Oncol."},{"key":"70725_CR67","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","volume":"187","author":"LP Andrews","year":"2024","unstructured":"Andrews, L. P. et al. LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity. Cell 187, 4355\u20134372 (2024).","journal-title":"Cell"},{"key":"70725_CR68","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1016\/j.cell.2024.07.004","volume":"187","author":"CT Kureshi","year":"2024","unstructured":"Kureshi, C. T., Dougan, M. & Dougan, S. K. Anti-LAG-3 boosts CD8 T cell effector function. Cell 187, 4144\u20134146 (2024).","journal-title":"Cell"},{"key":"70725_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","volume":"18","author":"G Chen","year":"2025","unstructured":"Chen, G. et al. Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial. J. Hematol. Oncol. 18, 15 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"70725_CR70","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1158\/0008-5472.CAN-03-3253","volume":"64","author":"W Xiong","year":"2004","unstructured":"Xiong, W. et al. A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res. 64, 1972\u20131974 (2004).","journal-title":"Cancer Res."},{"key":"70725_CR71","doi-asserted-by":"crossref","unstructured":"Cheung, C. C. et al. miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. Mol Cancer. 13, 184 (2014).","DOI":"10.1186\/1476-4598-13-184"},{"key":"70725_CR72","doi-asserted-by":"crossref","unstructured":"Lyu, X. et al. EBV-miR-BART1-5P activates AMPK\/mTOR\/HIF1 pathway via a PTEN independent manner to promote glycolysis and angiogenesis in nasopharyngeal carcinoma. PLoS Pathog. 14, e1007484 (2018).","DOI":"10.1371\/journal.ppat.1007484"},{"key":"70725_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52981-4","volume":"15","author":"J Ge","year":"2024","unstructured":"Ge, J. et al. Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma. Nat. Commun. 15, 8609 (2024).","journal-title":"Nat. Commun."},{"key":"70725_CR74","doi-asserted-by":"crossref","unstructured":"Ge, J. et al. FOXA1 enhances antitumor immunity via repressing interferon-induced PD-L1 expression in nasopharyngeal carcinoma. J. Immunother. Cancer 12, e010091 (2024).","DOI":"10.1136\/jitc-2024-010091"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70725-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70725-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:03:04Z","timestamp":1779753784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70725-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70725"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70725-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4647"}}